BRIEF—Therachon raises $60 million to fund rare disease efforts

Swiss biotech Therachon has raised $60 million in a financing round led by Novo Holdings, with money also from Cowen Healthcare Investments, Pfizer Ventures and others.

The proceeds will be used to advance the company’s lead pipeline candidate TA-46, a novel protein therapeutic for achondroplasia, the most common form of disproportionate short stature in humans. The candidate is currently in Phase I testing.

Therachon says it will add Jørgen Søberg Petersen of Novo Ventures and Timothy Anderson, VP of the Cowen Group, to its board.